| human | Q5 |
| P496 | ORCID iD | 0000-0003-2593-833X |
| P3829 | Publons author ID | 1176670 |
| P1053 | ResearcherID | H-6749-2019 |
| P1153 | Scopus author ID | 19735998600 |
| P27 | country of citizenship | Spain | Q29 |
| P735 | given name | Miguel | Q15620295 |
| Miguel | Q15620295 | ||
| P1412 | languages spoken, written or signed | Spanish | Q1321 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q48126340 | 24-h continuous infusion of platelets for patients with platelet transfusion refractoriness |
| Q100495755 | 50 years of Vox Sanguinis International Forums |
| Q91805762 | A methodological review of the quality of reporting of surveys in transfusion medicine |
| Q50542143 | A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. |
| Q36402628 | A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. |
| Q92610239 | A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe |
| Q85893877 | Acid-base balance disturbances in plasma exchange depend on the replacement fluid used |
| Q63581302 | Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges |
| Q73825873 | Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method |
| Q39150162 | An international survey on the role of the hospital transfusion committee. |
| Q38099101 | Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. |
| Q50744104 | Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. |
| Q54712502 | Apheresis activity in Spain: a survey of the Spanish Apheresis Group. |
| Q40246892 | Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. |
| Q43587730 | Automated preparation of whole blood-derived platelets suspended in two different platelet additive solutions and stored for 7 days. |
| Q38180463 | Automation of blood component preparation from whole blood collections. |
| Q89371448 | Borderline rejection in ABO-incompatible kidney transplantation |
| Q53308226 | Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series. |
| Q100429962 | CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies |
| Q40563039 | CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients |
| Q53538359 | Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. |
| Q47651286 | Coagulation profile after plasma exchange using albumin as a replacement solution measured by thromboelastometry |
| Q45267366 | Cocaine-induced acute hepatitis and thrombotic microangiopathy |
| Q44496156 | Comparison of plasma exchange procedures using three apheresis systems |
| Q91150538 | Complement Activation and Thrombotic Microangiopathies |
| Q81098195 | Consensus and controversies in platelet transfusion: trigger for indication, and platelet dose |
| Q53098496 | Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise. |
| Q72403373 | Cys209 Ser mutation in the platelet membrane glycoprotein Ib alpha gene is associated with Bernard-Soulier syndrome |
| Q40373480 | Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study. |
| Q86591832 | Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers |
| Q48122123 | Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information: summary |
| Q60912961 | Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions |
| Q53918403 | Diagnosis and treatment of acute humoral rejection after kidney transplantation: preliminary experience. |
| Q33418938 | Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group |
| Q47303070 | Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. |
| Q88931393 | Donor card |
| Q51038087 | Effect of holding buffy coats 4 or 18 hours before preparing pooled filtered PLT concentrates in plasma. |
| Q45194912 | Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. |
| Q73825870 | Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or -80 degrees C |
| Q92339443 | Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease |
| Q85304336 | Efficacy and safety of plasma exchange: ann 11-year single-center experience of 2730 procedures in 317 patients |
| Q55052808 | Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. |
| Q46803554 | Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib. |
| Q100465031 | Extracorporeal photopheresis is catching up the pole position |
| Q45051724 | Factors affecting red blood cell storage age at the time of transfusion |
| Q88220178 | Failed ABO incompatible high titers kidney transplant using bortezomib. Case report |
| Q33436722 | Fatal alloimmune thrombocytopenia due to anti-HLA alloimmunization in a twin pregnancy: A very infrequent complication of assisted reproduction |
| Q38096606 | Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. |
| Q48573392 | Frederic Duran-Jorda: a transfusion medicine pioneer |
| Q89624084 | Fulminant hepatitis A complicated by Takotsubo syndrome successfully treated with standard volume plasma exchange |
| Q71696913 | Glycoprotein IIb-IIIa and glycoprotein IV expression on Bernard-Soulier syndrome platelets |
| Q33359784 | Glycoproteins expression on platelet membrane in inherited macrothrombocytopenias |
| Q46897818 | Haptoglobin is present in albumin used as a replacement solution for plasma exchange |
| Q98284695 | Hemolysis in the plasma of a specimen? Add a drop to clarify it |
| Q81109303 | Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model |
| Q56460549 | Hepatitis E |
| Q86538910 | High Incidence of Paralytic Ileus After Bortezomib Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: Report of 2 Cases |
| Q91532093 | Home transfusion: three decades of practice at a tertiary care hospital |
| Q97680597 | Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature |
| Q64068295 | Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial |
| Q91301278 | Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program |
| Q90625184 | Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients |
| Q82064268 | Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function |
| Q89900885 | Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis |
| Q26775408 | Improving platelet transfusion safety: biomedical and technical considerations |
| Q40903255 | Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. |
| Q91142736 | Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis |
| Q80330512 | Improving the bacteriological safety of platelet transfusions |
| Q53317633 | In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. |
| Q89739165 | Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day |
| Q41671841 | Internal medicine resident knowledge of transfusion medicine: results from the BEST-TEST international education needs assessment. |
| Q47409155 | International Forum on GMP-grade human platelet lysate for cell propagation. |
| Q47565005 | International Forum on GMP-grade human platelet lysate for cell propagation: summary. |
| Q64125816 | International Forum on Occult hepatitis B infection and transfusion safety |
| Q48093275 | International Forum regarding practices related to donor haemoglobin and iron. |
| Q92011967 | International forum on Occult hepatitis B infection and transfusion safety |
| Q50438028 | Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study |
| Q93120987 | Leukocytapheresis in nonmobilized donors for cellular therapy protocols: Evaluation of factors affecting collection efficiency of cells |
| Q53563730 | Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. |
| Q35040235 | Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study |
| Q33374336 | Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials |
| Q33953403 | Matching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes. |
| Q97901162 | Medical student education in transfusion medicine, part II: Moving forward to building up a "Know How" education program in transfusion medicine for under-graduate medical students |
| Q77324155 | Modifications in accessibility of membrane glycoproteins, binding of specific ligands and coagulation factor V during the activation of platelets in blood emerging from bleeding time wounds |
| Q47586694 | Pathogen inactivation of platelet concentrates |
| Q48590344 | Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature |
| Q38150634 | Pathogen inactivation: coming of age. |
| Q89617029 | Peripheral venous access devices for apheresis: 16-gauge is not always needed |
| Q38757558 | Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients |
| Q98654247 | Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection |
| Q91566730 | Plasma exchange activity in the European Union |
| Q44834486 | Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. |
| Q91150155 | Plasma exchange in catastrophic antiphospholipid syndrome |
| Q38146098 | Plasma treated with methylene blue and light: clinical efficacy and safety profile. |
| Q73113373 | Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage |
| Q40594144 | Platelet concentrates: Balancing between efficacy and safety? |
| Q33392855 | Platelet dose for prophylactic platelet transfusions |
| Q77386518 | Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients |
| Q38594433 | Platelet transfusion and respecting patient D type |
| Q82050203 | Platelet transfusion in thrombotic thrombocytopenic purpura: between Scylla and Charybdis |
| Q82709221 | Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients |
| Q77297031 | Platelet-leukocyte activation during hemodialysis detected with a monoclonal antibody to leukocyte integrin CD11b |
| Q96303570 | Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial |
| Q39874781 | Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey. |
| Q87821291 | Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care |
| Q50597388 | Problems with irradiators. |
| Q33739495 | Quality indicators for Transfusion Medicine in Spain: a survey among hospital transfusion services |
| Q71335915 | Redistribution of membrane glycoproteins in platelets activated under flow conditions |
| Q81487206 | Risk of Rh(D) alloimmunization after transfusion of platelets from D+ donors to D- recipients |
| Q38215451 | Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness |
| Q100766026 | Role of therapeutic plasma exchanges in refractory severe warm autoimmune hemolytic anemia: Presentation of two case reports |
| Q46876784 | Sepsis caused by Capnocytophaga ochracea in a patient with acute leukemia |
| Q33434414 | Severe Babesia microti infection in an American immunocompetent patient diagnosed in Spain. |
| Q46444087 | Should DEHP be eliminated in blood bags? |
| Q81631240 | Stored platelets contain residual amounts of tissue factor: evidence from studies on platelet concentrates stored for prolonged periods |
| Q68640589 | Studies on the megakaryocytes of a patient with the Bernard-Soulier syndrome |
| Q90705142 | Successful use of nonantigen-specific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection |
| Q38411977 | Survival after ultramassive transfusion: a review of 1360 cases |
| Q47936522 | The Barcelona Hospital Clínic therapeutic apheresis database. |
| Q28218417 | The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin |
| Q43853723 | The addition of MESNA in vitro prolongs prothrombin time similar to N-acetyl cysteine. |
| Q101221756 | The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever |
| Q57787102 | The mesenchymal stem cell revealed |
| Q36796904 | The role of red blood cell exchange for severe imported malaria in the artesunate era: a retrospective cohort study in a referral centre |
| Q47799625 | Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials |
| Q37875273 | Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. |
| Q90961389 | Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis |
| Q46633350 | Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials |
| Q100509936 | Transfusion Medicine: overtime paradigm changes and emerging paradoxes |
| Q34500022 | Transfusion medicine as of 2014. |
| Q54390617 | Transfusion of incompatible RBCs to a patient with alloanti-Kp(b). |
| Q50251693 | Transfusion of irradiated red blood cell units with a potassium adsorption filter: A randomized controlled trial. |
| Q48158453 | Transfusion service management of sickle-cell disease patients |
| Q67955356 | Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass |
| Q94566848 | Vox Sanguinis International Forum on Donor Incentives |
| Q94566531 | Vox Sanguinis International Forum on Donor Incentives: Summary |
| Q94563899 | Vox Sanguinis International Forum on Transfusion Services about Response to COVID-19 |
| Q94664331 | Vox Sanguinis International Forum on Transfusion Services about Response to COVID-19 |
| Q48339570 | Vox Sanguinis International Forum on application of fetal blood grouping: summary. |
| Q43918665 | Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion-transmissible infections. |
| Q45240841 | Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion-transmissible infections: summary. |
| Q92007654 | Vox Sanguinis International Forum on paediatric indications for blood component transfusion |
| Q92007973 | Vox Sanguinis International Forum on paediatric indications for blood component transfusion: Summary |
| Q47565277 | Vox Sanguinis International Forum on platelet cryopreservation: Summary |
| Q48349038 | Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. |
| Q48349052 | Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary |
| Q94646378 | Vox Sanguinis International Forum on the selection and preparation of blood components for intrauterine transfusion: Summary |
| Q61783673 | Vox Sanguinis International Forum on the use of prehospital blood products and pharmaceuticals in the treatment of patients with traumatic haemorrhage |
| Q59442837 | Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary |
| Q94646093 | Vox Sanguinis International forum on the selection and preparation of blood components for intrauterine transfusion |
| Q69366670 | [Autoimmune hemolytic anemia preceding by 6 years an adenocarcinoma of the gallbladder] |
| Q67235954 | [Fusarium solani bronchopneumonia in a patient with acute myeloblastic leukemia] |
| Q81264699 | [Guide for transfusion of blood components] |
| Q71542933 | [Leukocyte content in platelet concentrates] |
| Q69575542 | [Pustulotic arthro-osteitis. An infrequent or little known disease?] |
Search more.